Mackenzie Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Mackenzie Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,139	Closed	-$230K	–	1674
2023 Q1	$230K	Sell	2,139 -54	-2%	-$6.22K	﹤0.01%	1299
2022 Q4	$241K	Buy	+2,193	New	+$142K	﹤0.01%	1165

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Mackenzie Financial's RXDX Position: Q2 2023 in Review

Mackenzie Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,139 shares — an estimated $230K sold.

Mackenzie Financial first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $241K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Mackenzie Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Mackenzie Financial sold 2,139 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $230K.
Mackenzie Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Mackenzie Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $241K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Mackenzie Financial's 13F filing for Q2 2023, filed 3 Aug 2023.